HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

ACADIA Pharmaceuticals Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

ACADIA Pharmaceuticals Intelligence Report

Generated from 3 signals · 3 evidence sources

Type

Company Intelligence Report

Generated

Aug 4, 2026

Confidence

Moderate Confidence · 71%

Evidence

15 items

Sources

11

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

ACADIA Pharmaceuticals maintains an active intelligence profile across Neurology, Parkinson's Disease, Alzheimer's Disease. 3 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 71% across 3 tracked sources. Highest-priority development: FDA AP — XTANDI (SUPPL). Regulatory precedent. Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for ACADIA Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. regulatory

    FDA AP — XTANDI (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  2. regulatory

    FDA AP — BREXAFEMME (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  3. regulatory

    Commissioner's National Priority Voucher (CNPV) Pilot Program

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    GDUFA III Drug Master File (DMF) Review Enhancements

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    FDA TA — CARBIDOPA; LEODOPA (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    FDA AP — COPAXONE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    FDA AP — LEVORPHANOL TARTRATE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    Search for Regulatory References | Drugs

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    FDA AP — NUPLAZID (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  11. regulatory

    S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers

    Regulatory precedent may inform portfolio positioning

    View detail
  12. regulatory

    Clinical trials for medicines: modifying a clinical trial approval

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 71 with buyer quality 6 (Emerging). Competitive pressure: Low. Portfolio impact: High.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • FDA AP — XTANDI (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — BREXAFEMME (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Commissioner's National Priority Voucher (CNPV) Pilot Program

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • GDUFA III Drug Master File (DMF) Review Enhancements

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA TA — CARBIDOPA; LEODOPA (ORIG)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — COPAXONE (SUPPL)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — LEVORPHANOL TARTRATE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Search for Regulatory References | Drugs

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — NUPLAZID (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Clinical trials for medicines: modifying a clinical trial approval

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: MHRA, MHRA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA grants priority review for NUPLAZID supplemental application

    Neurology · Parkinson's Disease

  • FDA Accepts Supplemental NDA for NUPLAZID by ACADIA PHARMS

    Neurology · Parkinson's Disease

  • ACADIA Pharmaceuticals initiates ACP-204 trials for Alzheimer's Disease Psychosis

    Neurology · Alzheimer's Disease

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.